Core Viewpoint - The cooperation between Huaren Pharmaceutical and the Feidong People's Government marks a significant step in the company's integrated strategy of "raw materials + formulations + packaging" and aims to boost the local biopharmaceutical industry while achieving mutual benefits for both the company and the local economy [1][2] Group 1: Project Overview - Huaren Pharmaceutical signed a cooperation framework agreement for a raw material production base project on December 10, 2025, located in the Hefei Circular Economy Demonstration Park, covering an area of approximately 100 acres [1] - The project will adhere to GMP standards and focus on the research and production of high-value-added raw materials in fields such as respiratory and narcotic medicine [1] Group 2: Strategic Importance - The construction of the Feidong raw material production base is a key component of Huaren Pharmaceutical's full industry chain layout, enhancing the company's competitive edge through integrated cost control and supply chain management [2] - The establishment of the base will improve the company's ability to control the entire process from upstream raw material development to downstream formulation processing, thereby increasing market competitiveness [2] Group 3: Economic Impact - The raw material production base is expected to inject new vitality into the industrial upgrade and economic growth of Feidong County, contributing to the development of a distinctive and advantageous biopharmaceutical industry cluster [2] - The project will promote the optimization of regional economic structure and elevate industrial capabilities, aligning with the characteristics of the biopharmaceutical industry as a strategic emerging sector with high added value and growth potential [2] Group 4: Future Outlook - The company plans to deepen its integrated strategic layout, using the Feidong raw material production base as a pivot to enhance research and innovation capabilities while ensuring the stability of the pharmaceutical supply chain [2] - This collaboration is seen as a significant step in the company's strategic implementation and a model for the deep integration of the pharmaceutical industry with local economies [2]

Core Viewpoint - The appointment of Jiang Ying as the new Secretary of the Board at Luoxin Pharmaceutical is a significant development, although her lack of experience in listed company secretary roles raises questions about her suitability for the position [3][6]. Company Overview - Luoxin Pharmaceutical, founded in 1988, has a diverse product range covering various medical fields including gastrointestinal diseases, pediatrics, oncology, and more [6]. - The company has experienced significant performance fluctuations in recent years, primarily due to the impacts of the COVID-19 pandemic, impairment provisions, and adjustments in financial liabilities [6]. Financial Performance - For the first half of 2025, Luoxin Pharmaceutical reported a revenue of 1.077 billion, a decrease of 14.45% year-on-year, while achieving a net profit attributable to shareholders of 17.695 million, marking a turnaround from losses in the previous year [6][7]. - The total revenue for the latest reporting period was 1.077 billion, with a total cost of 1.098 billion, resulting in an operating profit of 39.41 million, which is a 133.12% increase year-on-year [7]. - The net profit attributable to the parent company's shareholders was 17.695 million, reflecting a 119.95% increase compared to the same period last year [7]. Management Background - Jiang Ying, the newly appointed Secretary of the Board, has a strong academic background with dual degrees in Science and Economics from Peking University, as well as a Master's in Management from Peking University and a Master's in Finance from the University of Hong Kong [3][5]. - Prior to her appointment, Jiang Ying worked in various roles at Guotai Junan Securities, Everbright Pramerica Fund, and Guotai Fund, but lacks experience in listed company secretary positions [3][5].